Caterpillar Inc vs Charles River Laboratories Intl. Inc — how do they compare? Caterpillar Inc trades at $856.67 (market cap $387.68B), while Charles River Laboratories Intl. Inc trades at $287.99 (market cap $13.46B). The key difference: Caterpillar Inc is far larger — about 28.8× Charles River Laboratories Intl. Inc's market cap, and Caterpillar Inc pays a 0.77% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CAT | CRL | |
|---|---|---|
Market Cap | $387.68B | $13.46B |
Sector | Industrials | Health |
52-Week High | $1.06K | $282.00 |
52-Week Low | $407.79 | $145.57 |
Enterprise Value | $426.11B | $16.30B |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
Caterpillar (CAT) trades at $843.37, up 0.14% on the day, with strong year-to-date performance driven by robust earnings beats and AI data center demand. The stock shows a bearish technical signal but maintains solid fundamentals, including a net income margin of 14.51% and ROE of 56.99%. Recent news highlights growth from power and energy segments, with a dividend increase expected in June 2026.
Outlook remains positive due to earnings momentum and infrastructure tailwinds, though elevated valuation ratios like a P/E of 36.07 pose risks. Analyst consensus is bullish with a $1,010 price target, but investors should monitor economic cycles and competitive pressures that could impact future performance.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →